title: [Preliminary experience with hyperthermic intraperitoneal chemo-perfusion with oxaliplatin for the treatment of peritoneal carcinomatosis due to colorectal carcinoma].
abstract: Peritoneal carcinomatosis is the first cause of death after surgery for abdominal cancer, with a mean survival of 7 months. In selected patients, aggressive cytoreductive therapy combined with hyperthermic intraperitoneal chemotherapy my improve medium to long-term survival. Over the period from 2004 to January 2006, 86 patients were operated on for peritoneal carcinomatosis at the Division of Surgical Oncology, Forli, Italy. Thirteen of them were submitted to hyperthermic chemotherapy. The authors present their preliminary experience with the treatment of colorectal carcinosis by 30-min hyperthermic (41.5-42 degrees C intraperitoneal perfusion with oxaliplatin (400 mg/sq.m.) and intravenous 5-FU (400 mg/sq.m.) after complete cytoreductive surgery. The average surgical time was 606 min (range: 380-765). No intraoperative complications occurred, but 4 cases of major postoperative morbidity were reported, one of which requiring surgery. One patient died 5 months postoperatively due to lung metastases. The remaining patients are alive and free from peritoneal disease.
authors.affiliation: UO Chirurgia e Terapie Oncologiche Avanzate, Ospedale Morgagni-Pierantoni, Forlì.
authors.forename: Gianni
authors.initials: G
authors.lastname: Mura
authors.forename: Massimo
authors.initials: M
authors.lastname: Framarini
authors.forename: Alessio
authors.initials: A
authors.lastname: Vagliasindi
authors.forename: Davide
authors.initials: D
authors.lastname: Cavaliere
authors.forename: Francesca
authors.initials: F
authors.lastname: Tauceri
authors.forename: Gabriele
authors.initials: G
authors.lastname: Solfrini
authors.forename: Carlo
authors.initials: C
authors.lastname: Milandria
authors.forename: Giorgio Maria
authors.initials: GM
authors.lastname: Verdecchia
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002277:Carcinoma / Q000556:secondary / Q000628:therapy*; D010478:Chemotherapy, Cancer, Regional Perfusion / Q000379:methods*; D015179:Colorectal Neoplasms / Q000473:pathology / Q000628:therapy*; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced; D007263:Infusions, Parenteral; D007269:Injections, Intra-Arterial; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D000077150:Oxaliplatin; D010534:Peritoneal Neoplasms / Q000556:secondary / Q000628:therapy*; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin